Health care regulation, the Food and Drug Administration (FDA), and access to medicine: Our experience with dupilumab for children.

Wang, Chang Ye; Zheng, Rui Rui Chloe; Doerrer, Zachary A; Kurta, Anastasia O; Shelley, Jacob J; Siegfried, Elaine C

Wang, Chang Ye; Zheng, Rui Rui Chloe; Doerrer, Zachary A; Kurta, Anastasia O; Shelley, Jacob J; Siegfried, Elaine C.

Afiliación

Wang CY; Department of Dermatology, Saint Louis University, St Louis, Missouri. Electronic address: changye.wang@health.slu.edu.
Zheng RRC; Faculty of Law, University of Western Ontario, London, Ontario, Canada.
Doerrer ZA; School of Medicine, Saint Louis University, St Louis, Missouri.
Kurta AO; Department of Dermatology, Saint Louis University, St Louis, Missouri.
Shelley JJ; Faculty of Law, University of Western Ontario, London, Ontario, Canada; School of Health Studies, University of Western Ontario, London, Ontario, Canada.
Siegfried EC; Department of Dermatology, Saint Louis University, St Louis, Missouri.

J Am Acad Dermatol ; 82(6): 1568-1569, 2020 06.

Article en En | MEDLINE | ID: mdl-31958530

Asunto(s)

Anticuerpos Monoclonales Humanizados/uso terapéutico; Dermatitis Atópica/tratamiento farmacológico; Accesibilidad a los Servicios de Salud/legislación & jurisprudencia; United States Food and Drug Administration; Niño; Humanos; Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: United States Food and Drug Administration / Dermatitis Atópica / Anticuerpos Monoclonales Humanizados / Accesibilidad a los Servicios de Salud Límite: Child / Humans País/Región como asunto: America do norte Idioma: En Revista: J Am Acad Dermatol Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google